Liver glycogen storage disease type IX (GSD IX) accounts for 25% for all GSD cases, with a prevalence of 1 out of 100,000 patients. GSD IX is caused by deficiency in phosphorylase kinase (PhK), which is comprised of four subunits (α2, β, δ and γ2), with γ2 being the catalytic domain.
Recent studies indicate that the hyperactivation of the PD-1/PD-L1 axis in Alzheimer’s disease (AD) brain has an influence on disease pathophysiology. With this in mind, researchers from Sungkyunkwan University evaluated INR-301, a novel superior blood-brain barrier (BBB)-penetrating anti-PD-L1 antibody, in an AD model.
Arcus Biosciences Inc. has reported the discovery and SAR-driven optimization and characterization of potent novel tyrosine-protein kinase receptor UFO (AXL) inhibitors for the potential treatment of cancer.
Chimeric antigen receptor (CAR) T-cell therapy is a powerful approach for patients with hematologic malignancies, such as leukemia. Its broad use may be associated with life-threatening toxicities such as neurotoxicity and cytokine release syndrome (CRS).
RSS
